Abstract
Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resistance, defined as the inability of insulin to exert its metabolic actions, characterizes both T2DM and MetS. Recent data suggest that insulin resistance is directly implicated in atherosclerosis/restenosis, because of the unresponsiveness to the vasculoprotective action of insulin, including its phosphoinositide 3-kinase (PI3K)-Akt-endothelial nitric oxide synthase mediated enhancement of endothelial function. However, insulin also has ‘atherogenic’ actions, including enhancement of vascular smooth muscle cell (VSMC) proliferation, which are mitogen-activated protein kinase-mediated. These ‘atherogenic’ actions are less affected by insulin resistance, which mainly involves the PI3K pathway. The role of insulin in the atherosclerotic disease process is still highly controversial, where some investigators view insulin as a growth factor with pro-atherogenic effects while some others believe insulin resistance to be pro-atherogenic rather than insulin itself. We attempt to produce a balanced review with a focus on the effect of insulin in vivo, in animal models of atherosclerosis and restenosis.
Keywords: Insulin, restenosis, atherosclerosis, metformin, hypercholesterolemia, hyperinsulinemia, cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, glucose intolerance, hypertension, thiazolidinediones
Current Vascular Pharmacology
Title: Effects of Insulin on the Vasculature
Volume: 9 Issue: 3
Author(s): Danna M. Breen and Adria Giacca
Affiliation:
Keywords: Insulin, restenosis, atherosclerosis, metformin, hypercholesterolemia, hyperinsulinemia, cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, glucose intolerance, hypertension, thiazolidinediones
Abstract: Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resistance, defined as the inability of insulin to exert its metabolic actions, characterizes both T2DM and MetS. Recent data suggest that insulin resistance is directly implicated in atherosclerosis/restenosis, because of the unresponsiveness to the vasculoprotective action of insulin, including its phosphoinositide 3-kinase (PI3K)-Akt-endothelial nitric oxide synthase mediated enhancement of endothelial function. However, insulin also has ‘atherogenic’ actions, including enhancement of vascular smooth muscle cell (VSMC) proliferation, which are mitogen-activated protein kinase-mediated. These ‘atherogenic’ actions are less affected by insulin resistance, which mainly involves the PI3K pathway. The role of insulin in the atherosclerotic disease process is still highly controversial, where some investigators view insulin as a growth factor with pro-atherogenic effects while some others believe insulin resistance to be pro-atherogenic rather than insulin itself. We attempt to produce a balanced review with a focus on the effect of insulin in vivo, in animal models of atherosclerosis and restenosis.
Export Options
About this article
Cite this article as:
M. Breen Danna and Giacca Adria, Effects of Insulin on the Vasculature, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495558
DOI https://dx.doi.org/10.2174/157016111795495558 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoamine Receptors in the Regulation of Feeding Behaviour and Energy Balance
CNS & Neurological Disorders - Drug Targets Evaluation of In Vivo Efficacy of Aqueous Extract of Aerial Parts of Cynodon dactylon in Rats with Simultaneous Type 2 Diabetes and Hypertension
Current Bioactive Compounds The Negative Influence of Socio-Technical Developments on Eating Habits and Health
Current Nutrition & Food Science Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Stem Cell Therapies
Recent Patents on Regenerative Medicine Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Relationships of Birthweight and Postnatal Growth with Metabolic Risk Factors in Junior School Children in Korea
Current Hypertension Reviews Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Exercise-Induced Modulation of Endothelial Nitric Oxide Production
Current Pharmaceutical Biotechnology Hypertensive Cardiomyopathy in Asymptomatic Patients: A Neglected Diagnosis
Current Hypertension Reviews Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Impact of the Fontan Operation on Organ Systems
Cardiovascular & Hematological Disorders-Drug Targets Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Is There a Genetic Susceptibility to Bronchopulmonary Dysplasia?
Current Respiratory Medicine Reviews